Valneva Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Valneva de 50.9% y 20.8% por año respectivamente. Se prevé que el BPA crezca en un 55.8% al año. Se espera que la rentabilidad financiera sea de -17.9% en 3 años.

Información clave

21.7%

Tasa de crecimiento de los beneficios

33.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.7%
Tasa de crecimiento de los ingresos	22.3%
Rentabilidad financiera futura	-33.0%
Cobertura de analistas	Good
Última actualización	08 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 10

Recent updates

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 10

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Apr 05

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Mar 27

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Mar 15

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Jan 06

Industry Analysts Just Upgraded Their Valneva SE (EPA:VLA) Revenue Forecasts By 55%

Aug 13

Party Time: Brokers Just Made Major Increases To Their Valneva SE (EPA:VLA) Earnings Forecasts

Jul 28

Previsiones de crecimiento de beneficios e ingresos

ENXTPA:VLA - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	322	-23	3	-5	7
12/31/2025	234	-29	-1	-29	9
12/31/2024	190	3	-22	30	8
3/31/2024	153	-24	-222	-207	N/A
12/31/2023	154	-101	-217	-203	N/A
9/30/2023	223	-113	-208	-193	N/A
6/30/2023	431	-7	-231	-211	N/A
3/31/2023	373	-135	-266	-243	N/A
12/31/2022	361	-143	-275	-245	N/A
9/30/2022	439	73	-195	-149	N/A
6/30/2022	304	-159	-177	-108	N/A
3/31/2022	347	-72	-83	2	N/A
12/31/2021	348	-73	-16	77	N/A
9/30/2021	121	-248	15	97	N/A
6/30/2021	110	-125	51	109	N/A
3/31/2021	98	-91	147	182	N/A
12/31/2020	110	-64	118	138	N/A
9/30/2020	104	-62	67	78	N/A
6/30/2020	120	-25	97	105	N/A
3/31/2020	127	-8	-7	3	N/A
12/31/2019	126	-2	-5	6	N/A
9/30/2019	116	4	0	10	N/A
6/30/2019	109	1	10	16	N/A
3/31/2019	116	7	14	17	N/A
12/31/2018	113	3	13	16	N/A
9/30/2018	107	-7	4	6	N/A
6/30/2018	110	-7	8	10	N/A
3/31/2018	108	-8	2	5	N/A
12/31/2017	105	-11	N/A	13	N/A
9/30/2017	103	-11	N/A	17	N/A
6/30/2017	100	-14	N/A	19	N/A
3/31/2017	102	-46	N/A	25	N/A
12/31/2016	98	-49	N/A	7	N/A
9/30/2016	93	-63	N/A	4	N/A
6/30/2016	96	-61	N/A	-5	N/A
3/31/2016	89	-35	N/A	-17	N/A
12/31/2015	83	-21	N/A	-20	N/A
9/30/2015	74	-16	N/A	-24	N/A
6/30/2015	65	-13	N/A	-19	N/A
3/31/2015	55	-9	N/A	-15	N/A
12/31/2014	42	-26	N/A	-15	N/A
9/30/2014	41	-21	N/A	-6	N/A
6/30/2014	43	-28	N/A	-21	N/A
3/31/2014	41	-29	N/A	-27	N/A
12/31/2013	36	-24	N/A	-21	N/A
9/30/2013	26	-22	N/A	-27	N/A
6/30/2013	13	-14	N/A	-13	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que VLA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1%).

Beneficios vs. Mercado: Se prevé que VLA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que VLA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (20.8% al año) de VLA crezcan más rápidamente que los del mercado French (5.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (20.8% al año) de VLA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: VLA se prevé que no sea rentable en 3 años.

Valneva Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 19%

Forecast to breakeven in 2024

Valneva Se Announces Earnings Guidance for 2024

Consensus EPS estimates upgraded to €0.05 loss

Recent updates

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings released: EPS: €0.42 (vs €0.13 loss in 1Q 2023)

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Full year 2023 earnings released: €0.73 loss per share (vs €1.24 loss in FY 2022)

New minor risk - Profitability

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Consensus EPS estimates fall by 19%

Forecast to breakeven in 2024

Valneva Se Announces Earnings Guidance for 2024

Consensus EPS estimates upgraded to €0.05 loss

Consensus EPS estimates fall by 103%

Price target decreased by 8.6% to €9.17

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

No longer forecast to breakeven

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Consensus EPS estimates upgraded to €0.12 loss

Valneva Se Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Price target increased by 8.3% to €9.73

Forecast breakeven date moved forward to 2023

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

Valneva SE Provides Financial Guidance of 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Consensus EPS estimates fall by 91%, revenue upgraded

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Consensus forecasts updated

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

Price target decreased to €12.70

Is Valneva (EPA:VLA) Using Debt Sensibly?

No longer forecast to breakeven

No longer forecast to breakeven

Consensus forecasts updated

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001